drugset / Trial / NCT00004786
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis
Phase 3
Completed
200 enrolled
National Center for Research Resources (NCRR)
University of Pittsburgh · collab
RandomizedDouble-blindTreatment
Summary
OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis.
Timeline
- Start
- 1995-12
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iloprost | Other / unclassified | — | Oral |